Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
construction
release_alert
Profile editing is temporarily unavailable from
June 11-24, 2026
while manual profile data entry transitions to Elements.
Learn More
.
cancel
Amy Elizabeth Barto
Associate Professor of Medicine
Medicine, Gastroenterology
amy.barto@duke.edu
Office hours
Monday, Wednesday, Thursday and Friday 8am-5pm
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
Licensure
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Previous Appointments & Affiliations
Professional Training and Employment
Leadership & Clinical Positions
expertise {hide_children: true, active: false, enabled: false}
Expertise
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: false}
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: false}
Recognition
professional-activities {hide_children: true, active: false, enabled: false}
Professional Activities
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection
Clinical Trial
Principal Investigator ·
Awarded by Rebiotix Inc. ·
2021 - 2024
Smart Toilet with Artificial Intelligence for Remote Management of Inflammatory Bowel Disease
Research
Co Investigator ·
Awarded by Coprata LLC ·
2022 - 2024
A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection
Clinical Trial
Principal Investigator ·
Awarded by Rebiotix Inc. ·
2019 - 2021
